ASX - Delayed Quote AUD

AVITA Medical, Inc. (AVH.AX)

1.7100

-0.0850

(-4.74%)

As of 12:29:12 PM GMT+10. Market Open.

AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL

VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted data presented by researchers at the British Burn Association (BBA) Annual Meeting demonstrating reduced length of hospital stay among burn patients treated with RECELL®. The session, titled The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective, represents the la

GlobeNewswire 6 days ago

AVHHL

RCEL
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, published in the Journal of Surgery (Akpunonu et al., 2025). According to the investigators, Cohealyx demonstrated significantly faster wound bed vascularization and autograft readiness compared

GlobeNewswire 10 days ago

AVHHL

RCEL
AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards

VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the “Best New Technology Solution – Surgical” in the 2025 MedTech Breakthrough Awards. RECELL, FDA-approved for thermal burn wounds and full-thickness skin defects, has treated over 30,000 patients worldwide. RECELL requires sig

GlobeNewswire 12 days ago

AVHHL

RCEL
AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today

See how innovation is transforming patient outcomes through real-world clinical insights and patient storiesVALENCIA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, is hosting its Acute Wound Care Showcase 2025 virtually today, May 13, 2025, at 11:00 a.m. Pacific Time. Attendees will hear directly from leading burn and trauma clinicians using AVITA Medical’s technologies, a

GlobeNewswire last month

AVHHL

RCEL
Analysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest Report

As you might know, AVITA Medical, Inc. ( NASDAQ:RCEL ) last week released its latest first-quarter, and things did not...

Simply Wall St. last month

AVHHL

RCEL
AVITA Medical Reports First Quarter 2025 Financial Results

VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, design

GlobeNewswire last month

AVHHL

RCEL
AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

VALENCIA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will host its inaugural Acute Wound Care Showcase 2025 on Tuesday, May 13, 2025, via webcast at 11:00 a.m. Pacific Time. The event will feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs. The Acute Wound

GlobeNewswire last month

AVHHL

RCEL
AVITA Medical to Announce First Quarter 2025 Financial Results

VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its

GlobeNewswire last month

AVHHL

RCEL
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical’s expanded portfolio, including RECELL, Cohealyx, and PermeaDermVALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Ar

GlobeNewswire 2 months ago

AVHHL

RCEL
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and in

GlobeNewswire 2 months ago

AVHHL

RCEL
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm® Biosynthetic Wound Matrix, along with an Amendment to its existing Exclusive Distribution Agreement with Stedical Scientific, Inc. These agreements further strengthen the strategic relationship between the two companies to exp

GlobeNewswire 2 months ago

AVHHL

RCEL
Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 73.7% in Avita Medical (RCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

RCEL
AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

VALENCIA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Jim Corbett, Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at https://ir.av

GlobeNewswire 3 months ago

AVHHL

RCEL
AVITA Medical, Inc. (RCEL): A Bull Case Theory

We came across a bullish thesis on AVITA Medical, Inc. (RCEL) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RCEL. AVITA Medical, Inc. (RCEL)’s share was trading at $10.22 as of Feb 19th. Avita Medical (RCEL) reported its Q4 2024 and full-year earnings, with strong revenue growth and expanding market […]

Insider Monkey 3 months ago

RCEL
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know

The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 3 months ago

RCEL
AVITA Medical Full Year 2024 Earnings: Misses Expectations

AVITA Medical ( NASDAQ:RCEL ) Full Year 2024 Results Key Financial Results Revenue: US$64.3m (up 28% from FY 2023). Net...

Simply Wall St. 3 months ago

AVHHL

RCEL
AVITA Medical to Host Investor Webinar Briefing

VALENCIA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time). The

GlobeNewswire 3 months ago

AVHHL

RCEL
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business Updates Commercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023Gross profit margin of 87.6%On December 19, 2024,

GlobeNewswire 3 months ago

AVHHL

RCEL
AVITA Medical's shares sink 19% after another forecast cut

AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target. The U.S.-based company estimated its commercial revenue was about $64.3 million in fiscal 2024, lower than its forecast of $68 million to $70 million, due to slower-than-expected purchases from hospitals in the last quarter. AVITA's shares tumbled 18.8% to a two-month low of A$3.53, while the broader S&P/ASX 200 healthcare index was 0.7% higher.

Reuters 5 months ago

RCEL
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

VALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its fourth quarter and full-year 2024 commercial revenue guidance. For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be approximately $18.4 million, reflecting growth of around 30% over the same period i

GlobeNewswire 5 months ago

AVHHL

RCEL

Performance Overview

Return	AVH.AX	S&P 500 (^GSPC)
YTD	-59.76%	+1.62%
1-Year	-34.23%	+10.04%
3-Year	+18.75%	+63.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AVITA Medical, Inc. (AVH.AX)

AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL

AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards

AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today

Analysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest Report

AVITA Medical Reports First Quarter 2025 Financial Results

AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

AVITA Medical to Announce First Quarter 2025 Financial Results

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?

AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

AVITA Medical, Inc. (RCEL): A Bull Case Theory

Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know

AVITA Medical Full Year 2024 Earnings: Misses Expectations

AVITA Medical to Host Investor Webinar Briefing

AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

AVITA Medical's shares sink 19% after another forecast cut

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

Performance Overview